1 / 15

Day1 Plenary Session

Day1 Plenary Session. Lecture 1 : Propagation of the neurodegenerative process in PD and the Prion-like hypothesis. Lecture 2 : Can the interaction between genetics, environment, and behavior be a key determinant of PD expression.

yardan
Télécharger la présentation

Day1 Plenary Session

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Day1Plenary Session Lecture 1: Propagation of the neurodegenerative process in PD and the Prion-like hypothesis Lecture 2: Can the interaction between genetics, environment, and behavior be a key determinant of PD expression Lecture 3: What epidemiological and preclinical studies teach us about inflammation and PD Lecture 4: Developing new treatments founded on the basic science of PD Special Lecture 1:The Life and Times of James Parkinson Special Lecture 2:The Glory of Canadian Sciences and Parkinson's Disease

  2. Day 2Plenary Session Lecture 1: The spectrum of non-motor symptoms in PD Lecture 2: Dementia and psychiatric manifestations in PD Lecture 3: Contribution of functional neuroimaging to the understanding of non-motor manifestations of PD Lecture 4: The impact of other medical conditions on the course of PD WPC James Parkinson Lecture: Past, Present and Future of Parkinson’s Disease

  3. Day 3Plenary Session Lecture 1: Cell and gene-based technologies for restorative and neuroprotective therapies Lecture 2: Exercise, diet, and other lifestyle activities as treatments for Parkinson disease Lecture 3:Empowered patients and how they can help improve healthcare Lecture 4:Roles for healthcare professionals: multidisciplinary care for Parkinson disease. Special Lecture:Living Positively After a Diagnosis of Parkinson's

  4. Day 1 Parallel Session I Parallel Session: New genes and risk factors of PD Lecture 1: New PD genes and rare variants Lecture 2: Risk factors for sporadic PD Lecture 3: Genetics and gene environment interactions Parallel Session: Protein misfolding as a key pathogenic event Lecture 1: Alpha-synuclein conformation and neurodegeneration Lecture 2:Protein misfolding in neurodegenerative diseases Lecture 3: Link between lysosomal function and neurodegeneration in PD Parallel Session: Role of functional imaging modalities in the diagnosis and managementof PD Lecture 1: Structural imaging for PD: MRI and transcranial sonography (TCS) Lecture 2: Neurochemical imaging Lecture 3: Functional connectivity Parallel Session: Non-dopaminergic systems in PD: Anatomy, Biochemistry, and Pathology Lecture 1: Role of noradrenaline and serotonin systems for the development of non-motor symptoms Lecture 2: Impact of cholinergic dysfunction on the development of non-motor symptoms Lecture 3: Role of non-dopaminergic systems in the development of L-DOPA-induced dyskinesias

  5. Day 1 Parallel Session I Workshop 1:Why supporting research is crucial: from government to private funding agencies Workshop 2: Mitochondrial defect in PD: myth or reality? Workshop 3: Sexual issues in Parkinson's disease: assessment and intervention Workshop 4:Quality of life and comfort in the late stages of Parkinson's disease

  6. Day 1 Parallel Session II Parallel Session: Quality of life in Parkinson’s disease: several important determinants Lecture 1: Practical solutions to driving, early job loss, and relationship issues Lecture 2: Psychological solutions to dealing with pity, dignity, sense of worth and communication Lecture 3:Physical solutions to coping with pain, motor/non-motor, cognition, mood, and behavior Parallel Session: How Parkinson’s affects attention and memory Lecture 1: Memory and attention issues in Parkinson’s disease—clinical characteristics and mechanisms Lecture 2: Clinical Assessment of Cognition in PD Lecture 3: Practical management of cognitive deficits in Parkinson's disease; what can occupational therapists offer? Parallel Session: Experimental models of non-motor manifestations of PD Lecture 1: Animal models of hyper dopaminergic behavior in Parkinson’s disease Lecture 2: Animal models of sleep disorders in Parkinson’s disease Lecture 3: Animal models of gastrointestinal dysfunction in Parkinson’s disease Parallel Session: Optogenetic tools to study PD pathophysiology Lecture 1: Optical Neural Engineering Lecture 2: Regulation of Parkinsonian motor behaviors by optogenetic control of basal ganglia circuitry Lecture 3: Optical Interrogation of the dopaminergic systems

  7. Day 1 Parallel Session II Workshop 1: Everything you always wanted to know about genetics and that you never dared to ask Workshop 2: Howresearchers and people with Parkinson’s can advance clinical trials together Workshop 3: How drugs make it to your cabinet Workshop 4: Music, art, creativity and Parkinson's

  8. Day 2 Parallel Session I Parallel Session: PD or not PD - that is the question: Is it time to redefine/reclassify Parkinson’s disease? Lecture 1: Current definitions and diagnostic criteria: reasons for redefining the disorder. Lecture 2: The challenge of "prodromal" Parkinson's disease Lecture 3: Redefining Parkinson's disease: possible approaches to developing new diagnostic criteria Parallel Session: Hallucinations and related phenomena in PD Lecture 1: Prototypical and less common hallucinations Lecture 2: Where is the nucleus hallucinatorius and how it gets stimulated? Lecture 3: Management of hallucinations and related symptoms Parallel Session: Mitochondrial quality control mechanisms Lecture 1: Mitochondrial quality control- a matter of life and death for neurons Lecture 2: Mechanisms of mitophagy in Parkinson’s disease Lecture 3: Mitochondrial remodeling in the control of apoptosis Parallel Session: Ways for people with Parkinson’s to become empowered Lecture 1: Why and how people with Parkinson’s need empowerment - Finding your own niche Lecture 2: Evidence-based self-management practices Lecture 3: Increasing Parkinson’s advocacy effectiveness with lessons learned from other diseases

  9. Day 2 Parallel Session I Workshop 1: Benefits and risks of genetic testing Workshop 2: Sleep and fatigue in PD Workshop 3:Ethical dilemmas posed by new diagnostic and therapeutic technologies Workshop 4:Tricks of the trade: clever strategies to improve mobility

  10. Day 2 Parallel Session II Parallel Session: PD or look-alikes: how to diagnose them and what are their long-term prognoses? Lecture 1: Drug Induced Parkinsonism Lecture 2: PD or progressive supranuclear palsy Lecture 3: PD or Multiple system atrophy Parallel Session: Clinical trial outcomes—What do they really mean? Lecture 1: Clinical trial endpoints in PD – What is really meaningful? Lecture 2: The placebo effect: how it complicates clinical trial results Lecture 3: Slowing clinical progression in PD –can it be proven in clinical trials? Parallel Session: The search for new delivery methods for drugs Lecture 1: Improving oral drug delivery in PD – recent advances Lecture 2: Infusion therapies and other non-oral routes of drug delivery Lecture 3: Delivering therapeutic genes into the brain – a future way of drug delivery? Parallel Session: Is PD an axonopathy? Lecture 1: Pathological evidence for axonopathy in Parkinson’s disease Lecture 2: Evidence for synaptic dysfunction in Parkinson’s disease Lecture 3: Alterations in axonal transport in Parkinson’s disease

  11. Day 2 Parallel Session II Workshop:Choosing a care facility: When is it time? What are the options? Workshop: Do experimental models of Parkinson’s disease predict treatment outcome? Workshop: Complementary and integrative medicine Workshop: Dance and Parkinson’s: Why and How?

  12. Day 3 Parallel Session I Parallel Session: Update on Gaucher and Parkinson's diseases Lecture 1: What is new about the link between Gaucher mutations and Parkinsonism Lecture 2: Exploring mechanisms that underlie between mutations in Gaucher disease gene and synucleinopathy risk Lecture 3: How the understanding of Gaucher could lead to new therapies for Parkinson's Parallel Session: Newinsights into Parkinson's disease from experimental cell- and gene-based strategies Lecture 1: Use of human ES and iPS cells for cell replacement in Parkinson´s disease Lecture 2: Role of Sonic hedgehog in maintaining striatal homeostasis Lecture 3: Nurr1 as a therapeutic target for neuroprotection and disease modification in PD Parallel Session: Neurobiology and treatment of dyskinesias Lecture 1: Maladaptive plasticity in L-DOPA-induced dyskinesia: emerging role of serotonin transmission and other presynaptic factors Lecture 2: Pre- and post-synaptic molecular mechanism underlying L-DOPA-induced dyskinesia possible new pharmacological targets Lecture 3: Multiple dopamine-dependent synaptic mechanisms underlying dyskinesia in animal models Parallel Session: Pathophysiology and management of head drop and bent spine in PD: Are they dystonia or myopathy or both? Lecture 1: Myopathy causing camptocormia in idiopathic Parkinson's disease Lecture 2: Camptocormia: pathogenesis, classification, and response to therapy Lecture 3: Dropped head syndrome in Parkinson's disease

  13. Day 3 Parallel Session I Workshop 1: Whatyou need to know about DBS: Selection, side effects, and new device development Workshop 2:Is PD an accelerated form of aging? Workshop 3: Pain in PD Workshop 4: Speech and Parkinson’s

  14. Day 3 Parallel Session II Parallel Session: Freezing and falls Lecture 1: Freezing- Underlying mechanisms and the role of cueing Lecture 2: Why do persons with PD fall? Does treatment help to reduce falling? Lecture 3: The benefits of exercise in reducing falling in PD Parallel Session: Promising approaches to identify and validate biomarkers Lecture 1: What are biomarkers and why do we need them? Lecture 2: Update on unbiased methodologies to identify biomarkers Lecture 3: Emerging biomarkers Parallel Session: Drug development challenges: from the pharmaceutical industry, regulatory agencies, and patient protection organizations perspective Lecture 1: Drug development challenges-Pharmaceutical industry perspective Lecture 2: Drug development challenges - A regulatory perspective Lecture 3: Drug development challenges-Patient protection agency perspective Parallel Session: How should levodopa induced dyskinesia be managed today? Lecture 1: Recognizing the subtypes and assessing severity of dyskinesia and the clinical impact Lecture 2: Current management of LID – medical and surgical Lecture 3:Future Management of LID: What’s in the pipeline?

  15. Day 3 Parallel Session II Workshop 1: The role of people with Parkinson's in the research process: How are they prepared and what can they do? Workshop 2: Which physical and mental exercises are good for people with Parkinson’s? Workshop 3: Parkinson's and Mood Changes: Depression, Apathy and Anxiety

More Related